Financing channel feed – Endpoints News

SIGN UP

Financing channel feed

A biotech fledgling cross-bred in France and Switzerland launches to take on liver problems of global dimensions

7 years ago

Eyeing RNAi potential in cancer and fibrosis, trans-Pacific biotech Sirnaomics lines up $47M Series C

7 years ago

Three biotechs reveal some secrets about themselves as they gun for $271M-plus in IPOs

7 years ago

Nine listings and $3.8B later, HKEX celebrates one-year biotech anniversary with $194M CRO IPO

7 years ago

Touting superior nasal delivery, Satsuma bags $62M for new formulation of old migraine drug

7 years ago

Long on ideas but short on experience? Start Codon has some cash and a place for you in the Golden Triangle

7 years ago

Watch out bluebird bio. A little biotech just got Novartis’ backing to break out of the back field and race you to the finish line with a BCMA CAR-T

7 years ago

Biotech vet Troy Wilson shines a spotlight on his oligonucleotide startup as Eli Lilly signs up for a premier Big Pharma partnership

7 years ago

Gilead-partnered Vienna-based immunotherapy company Hookipa makes Nasdaq debut with downsized $84M IPO

7 years ago

Serial biotech entrepreneur Michael Gilman takes his key to the $100M-plus club and goes all-in on drugging RNA

7 years ago

On a mission to make organ transplants safer and more durable, Blackstone gifts Talaris a new CEO, leads $100M round

7 years ago

Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic development

7 years ago

Flagship unveils gut-focused upstart Kintai, with former GSK exec as chief

7 years ago

With $150M and a new NASH discovery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world

7 years ago

Four biotech Nasdaq wannabes outline IPO plans — and don't miss Chi-Med's HKEX pitch

7 years ago

This venture player is plotting $200M in new biotech investing — and they’re doubling down on a startup-rich strategy

7 years ago

This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX

7 years ago

Sonde wants to listen for disease — M Ventures heard the Boston biotech, and led a $16M round to supercharge research

7 years ago

Still early stage, but this Flagship upstart recruited a Big Pharma exec with a $4.3M compensation package and an IPO plan

7 years ago

Jude Samulski's gene therapy company just raised $235M for clinical development

7 years ago

Inozyme brings $67M to the bank to build up its calcification-focused rare disease pipeline

7 years ago

Gene therapies for the cats and dogs you love? Penn-partnered Scout Bio just raised $20M to make it a reality

7 years ago

Can Trevi make it through the IPO window with an old opioid that failed their key PhII?

7 years ago

NGM bags $107M from an IPO designed to back their play in the big NASH R&D race

7 years ago

First page Previous page 112 113 114115116 117 118 Next page Last page